Klotho Neurosciences Shareholders Approve Reverse Stock Split

Klotho Neurosciences ( (KLTO) ) has shared an announcement.

At a special meeting of stockholders held on February 17, 2026, Klotho Neurosciences, Inc. obtained shareholder approval to amend its certificate of incorporation to implement a reverse stock split of its common shares at a ratio between 1-for-2 and 1-for-50, with the exact ratio to be set by the board. The meeting, based on a January 15, 2025 record date with 73,536,722 shares outstanding and a quorum of 30,457,004 shares represented, recorded 27,637,476 votes in favor, 2,642,876 against and 176,650 abstentions on the reverse split proposal.

Stockholders also approved an amendment to the company’s 2024 Equity Incentive Plan to increase the pool of common shares available for issuance to 10,000,000, subject to certain conditions. This measure, which passed with 11,082,522 votes for, 3,609,008 against and 45,960 abstentions, enhances Klotho Neurosciences’ flexibility to grant equity-based compensation, potentially aiding talent retention and alignment with shareholder interests, while rendering a planned adjournment proposal unnecessary.

More about Klotho Neurosciences

Klotho Neurosciences, Inc. operates in the biopharmaceutical and neuroscience sector, focusing on developing treatments targeting neurological conditions. The company is publicly held, with its common stock actively held by a broad base of stockholders who participate in key corporate governance decisions such as capital structure changes and equity incentive plans.

Average Trading Volume: 696,875

Technical Sentiment Signal: Sell

Current Market Cap: $16.24M

For a thorough assessment of KLTO stock, go to TipRanks’ Stock Analysis page.